Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with Bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: Results of an EORTC genito-urinary group randomized phase 2 trial (30993)

European Urology

Volumn 59, Issue 3, 2011, Pages 438-446

  Oosterlinck, Willem ^a   Kirkali, Ziya ^b   Sylvester, Richard ^c   Silva, Fernando Calais Da ^d   Busch, Christer ^e   Algaba, Ferran ^f   Collette, Sandra ^c   Bono, Aldo ^g  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c EORTC DATA CENTER   (Belgium)

^d Centro Hospitalar de Lisboa Central   (Portugal)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f FUNDACIÓ PUIGVERT   (Spain)

^g OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Bacillus Calmette Gu rin; Carcinoma in situ; Intravesical therapy; Mitomycin C; Non muscle invasive bladder cancer; Randomized clinical trial; Urinary bladder

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RECURRENCE; CARCINOMA IN SITU; CYSTITIS; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FEVER; DRUG INSTILLATION; DRUG WITHDRAWAL; DYSURIA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT RESPONSE; URINARY FREQUENCY; URINE INCONTINENCE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA IN SITU; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TRANSURETHRAL RESECTION OF PROSTATE; URINARY BLADDER NEOPLASMS;

EID: 79551469096     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.11.038     Document Type: Article

References (21)

1. M.C. Hall, S.S. Chang, and G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1and Tis): 2007 update J Urol 178 2007 2314 2330
2. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, and J. Palou-Redorta EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
3. A.P.M. van der Meijden, R. Sylvester, and W. Oosterlinck EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ Eur Urol 48 2005 363 371
4. P. Rajala, E. Kaasinen, and E. Rintala Cytostatic effect of different strains of Bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha Urol Res 20 1992 215 217
5. A. Erol, S. Ozgur, M. Basar, and S. Cetin Trial with bacillus Calmette-Guerin and epirubicin combination in the prophylaxis of superficial bladder cancer Urol Int 52 1994 69 72
6. Y. Uekado, A. Hirano, T. Shinka, and T. Ohkawa The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report Cancer Chemother Pharmacol 35 Suppl 1994 S65 S68
7. A.V. Bono, J.A. Lovisolo, and G. Saredi Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer Eur Urol 37 2000 478 483
8. T.R. Fleming One-sample multiple testing procedure for phase II clinical trials Biometrics 38 1982 143 151
9. P. Gontero, A. Bohle, and P.U. Malmstrom The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer Eur Urol 57 2010 410 429
10. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
11. E. Rintala, K. Jauhiainen, P. Rajala, M. Ruutu, E. Kaasinen, and O. Alfthan Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group J Urol 154 1995 2050 2053
12. J.A. Witjes, C.T. Caris, N.A. Mungan, F.M. Debruyne, and W.P. Witjes Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer J Urol 160 1998 1668 1671
13. A.P.M. Van der Meijden, R.R. Hall, M.P. Macaluso, A. Pawinsky, R. Sylvester, and M. Van Glabbeke Marker tumour response to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours: Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897) Eur Urol 29 1996 199 203
14. E. Rintala, K. Jauhiainen, E. Kaasinen, M. Nurmi, O. Alfthan Finnbladder Group Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer J Urol 156 1996 56 59 discussion 59-60
15. G. Jakse, R. Hall, and A. Bono Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861 Eur Urol 40 2001 144 150
16. T.M. de Reijke, K.H. Kurth, and R.J. Sylvester Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906) J Urol 173 2005 405 409
17. E. Kaasinen, H. Wijkström, and P.U. Malmström Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study Eur Urol 43 2003 637 645
18. E. Kaasinen, E. Rintalla, and P. Hellström Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma Eur Urol 42 2002 167 174
19. T. Cai, G. Nesi, and G. Tinacci Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with non-muscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study J Urol 180 2008 110 115
20. S.M. Di Stasi, A. Giannantoni, and A. Giurioli Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial Lancet Oncol 7 2006 43 51
21. El Mohsen MA, Shelbaia A, El Ghobashy S, et al. Sequential chemoimmunotherapy using Mitomycin followed by bacillus Calmette-Guérin versus single agent immunotherapy (BCG) for recurrent superficial bladder tumors. UroToday Int J 2010;3. doi:10.3834/uij.1944-5784.2010.06.06.